Home › Interim Data from Proof-of-Concept Study of Merck's Investigational...
 

Keywords :   


Interim Data from Proof-of-Concept Study of Merck's Investigational...

2014-11-10 08:38:26| Biotech - Topix.net

Merck , known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir , the company's investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide inhibitor for the treatment of chronic hepatitis C virus infection.

Tags: data study interim investigational

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Atlantic Tropical Weather Outlook
29.06Eastern North Pacific Tropical Weather Outlook
28.06What we learned from IT expert at Post Office inquiry
28.06M&S to launch clothing repairs service
28.06Tropical Depression Two Graphics
28.06Tropical Depression Two Public Advisory Number 1
28.06Summary for Tropical Depression Two (AT2/AL022024)
28.06Tropical Depression Two Forecast Advisory Number 1
More »